

Table S1. Drug susceptibility prediction: single classes and combinations are reported, expressed as absolute number of patients harbouring DRMs out of total of patients enrolled in each year.

	NRTI^a	NNRTI^b	PI^c	N+NNRTI	NRTI+PI	NNRTI+PI	3 drug classes	Total
	<i>n</i>	<i>n</i>	<i>n</i>	<i>n</i>	<i>n</i>	<i>n</i>	<i>n</i>	<i>n</i>
B-type								
2017	3	9		2				14/84
2018	2	11	1					14/63
2019	2	5						7/80
2020	2	3				1		6/41
2021		6	1				1	8/46
2022	1	3						4/34
2023	1	4						5/38
2024		1						1/8
NonB-type								
2017		5						5/73
2018		8	1					9/62
2019	1	7						8/52
2020	1	3						4/29
2021		2	1					3/33
2022		6	1					7/48
2023	1	14	1	1	1			18/62
2024		3						3/9

^a Nucleoside Reverse Transcriptase Inhibitors; ^b Non-nucleoside Reverse Transcriptase Inhibitors;

^c Protease Inhibitors.